Amarantus BioScience - “Ophthalmology: MANF’s Orphan Strategy Coming into Focus in Retinitis Pigmentosa”


Amarantus BioScience, Inc. (AMBS) today published a new blog post on The Chairman’s Blog, written by the company’s President and CEO, Gerald Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Amarantus President and CEO, Gerald Commissiong, blogs about the company’s lead therapeutic program, MANF, and its orphan strategy in the ophthalmology field. He stresses, among other things, the successful company strategies he’s seen; “A prime example of a successful orphan strategy is Genzyme, who was successful in turning its orphan drug strategy into a $20.1B buyout by Sanofi Aventis (SNY) in 2011. Another example of a successful orphan strategy is FerroKin Biosciences, who was successfully acquired by Shire (SHPG) for $325M in early 2012 with only $27M in paid-in-capital and a virtual staff of 7 employees. In 2011, Alexion Pharmaceuticals (ALXN) reported $783M in revenue based on sales of its only product Soliris, a drug that treats a population of approximately 10,000 patients in the US and Western Europe.” Read the full blog post on (

About Amarantus BioScience, Inc.

AmarantusBioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson’s disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information, please visit

About is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.

Source: Amarantus BioScience, Inc.

View Comments (0)